期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 128, 期 6, 页码 2600-2612出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI98709
关键词
-
资金
- NIH [R00DK97455, R01DK112943, P30DK063608, P01HL087123]
- Office of the Director, NIH [S10OD020056]
- Diabetes and Endocrinology Research Center [P30DK063608]
- NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL087123] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R00DK097455, R01DK112943, P30DK063608, P30DK026687] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [K01AG045335, R01AG056387] Funding Source: NIH RePORTER
- OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD020056] Funding Source: NIH RePORTER
Thiazolidinediones (TZDs) are PPAR gamma agonists with potent insulin-sensitizing effects. However, their use has been curtailed by substantial adverse effects on weight, bone, heart, and hemodynamic balance, TZDs induce the deacetylation of PPAR gamma on K268 and K293 to cause the browning of white adipocytes. Here, we show that targeted PPAR gamma mutations resulting in constitutive deacetylation (K268R/K29SR, 2KR) increased energy expenditure and protected from viscera I adiposity and diet-induced obesity by augmenting brown remodeling of white adipose tissues. Strikingly, when 2KR mice were treated with rosiglitazone, they maintained the insulin-sensitizing, glucose-lowering response to TZDs, while displaying little, if any, adverse effects on fat deposition, bone density, fluid retention, and cardiac hypertrophy. Thus, deacetylation appears to fulfill the goal of dissociating the metabolic benefits of PPAR gamma activation from its adverse effects. Strategies to leverage PPAR gamma deacetylation may lead to the design of safer, more effective agonists of this nuclear receptor In the treatment of metabolic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据